183 related articles for article (PubMed ID: 17178266)
1. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
Kirchheiner J; Thomas S; Bauer S; Tomalik-Scharte D; Hering U; Doroshyenko O; Jetter A; Stehle S; Tsahuridu M; Meineke I; Brockmöller J; Fuhr U
Clin Pharmacol Ther; 2006 Dec; 80(6):657-67. PubMed ID: 17178266
[TBL] [Abstract][Full Text] [Related]
2. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
3. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.
Pedersen RS; Damkier P; Brosen K
Br J Clin Pharmacol; 2006 Dec; 62(6):682-9. PubMed ID: 16856883
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
Niemi M; Leathart JB; Neuvonen M; Backman JT; Daly AK; Neuvonen PJ
Clin Pharmacol Ther; 2003 Oct; 74(4):380-7. PubMed ID: 14534525
[TBL] [Abstract][Full Text] [Related]
5. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.
Niemi M; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2004 Sep; 76(3):239-49. PubMed ID: 15371985
[TBL] [Abstract][Full Text] [Related]
6. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
7. Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects.
Kim KA; Park PW; Kim HK; Ha JM; Park JY
J Clin Pharmacol; 2005 Aug; 45(8):941-6. PubMed ID: 16027405
[TBL] [Abstract][Full Text] [Related]
8. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.
Tornio A; Niemi M; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2008 Jan; 36(1):73-80. PubMed ID: 17913794
[TBL] [Abstract][Full Text] [Related]
9. Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans.
Kim KA; Park PW; Kim KR; Park JY
Br J Clin Pharmacol; 2007 Mar; 63(3):339-45. PubMed ID: 16981900
[TBL] [Abstract][Full Text] [Related]
10. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects.
Park JY; Kim KA; Kang MH; Kim SL; Shin JG
Clin Pharmacol Ther; 2004 Mar; 75(3):157-62. PubMed ID: 15001966
[TBL] [Abstract][Full Text] [Related]
11. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
12. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Thijssen HH; Ritzen B
Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
[TBL] [Abstract][Full Text] [Related]
13. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
[TBL] [Abstract][Full Text] [Related]
14. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects.
Park JY; Kim KA; Shin JG; Lee KY
Br J Clin Pharmacol; 2004 Oct; 58(4):397-402. PubMed ID: 15373932
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
[TBL] [Abstract][Full Text] [Related]
16. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.
Tomalik-Scharte D; Fuhr U; Hellmich M; Frank D; Doroshyenko O; Jetter A; Stingl JC
Drug Metab Dispos; 2011 May; 39(5):927-32. PubMed ID: 21270106
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.
Kim KA; Park PW; Lee OJ; Choi SH; Min BH; Shin KH; Chun BG; Shin JG; Park JY
Clin Pharmacol Ther; 2006 Dec; 80(6):646-56. PubMed ID: 17178265
[TBL] [Abstract][Full Text] [Related]
18. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.
Aquilante CL; Bushman LR; Knutsen SD; Burt LE; Rome LC; Kosmiski LA
Hum Genomics; 2008 Sep; 3(1):7-16. PubMed ID: 19129086
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
20. Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids.
Kirchheiner J; Meineke I; Fuhr U; Rodríguez-Antona C; Lebedeva E; Brockmöller J
Pharmacogenomics; 2008 Mar; 9(3):277-88. PubMed ID: 18303964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]